汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002412 汉森制药

已收盘 12-23 15:00:00

{"stockData":{"symbol":"002412","market":"SZ","secType":"STK","nameCN":"汉森制药","latestPrice":6.71,"timestamp":1766473407000,"preClose":6.73,"halted":0,"volume":6154700,"delay":0,"changeRate":-0.003,"floatShares":498000000,"shares":503000000,"eps":0.3419,"marketStatus":"已收盘","change":-0.02,"latestTime":"12-23 15:00:00","open":6.73,"high":6.84,"low":6.68,"amount":41459100,"amplitude":0.0238,"askPrice":6.72,"askSize":167,"bidPrice":6.71,"bidSize":109,"shortable":0,"etf":0,"ttmEps":0.3419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":5,"adr":0,"adjPreClose":6.73,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":7.4,"lowLimit":6.06,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":503200000,"isCdr":false,"pbRate":1.5,"roa":"--","peRate":19.625622,"roe":"3.69%","epsLYR":0.4377,"committee":0.449845,"marketValue":3376000000,"turnoverRate":0.0124,"status":1,"floatMarketCap":3341000000},"requestUrl":"/m/hq/s/002412","defaultTab":"news","newsList":[{"id":"2593889174","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593889174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593889174?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:54","pubTimestamp":1766393661,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司到十二月二十日的股东人数，谢谢汉森制药回复：尊敬的投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200019844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2592164248","title":"汉森制药：坚守中成药主业做大做强","url":"https://stock-news.laohu8.com/highlight/detail?id=2592164248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592164248?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148720,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司有考虑加大中药研究和发扬光大中药吗？谢谢汉森制药回复：尊敬的投资者您好，公司“一体两翼”发展战略中，明确了坚守中成药主业，立足中成药主业进行产业延伸和融合，通过内生增长和外延发展“双轮驱动”，做大做强中成药主业。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2591616226","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616226?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:09","pubTimestamp":1765786149,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日股东人数是多少？汉森制药回复：尊敬的投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500015157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2590375842","title":"汉森制药：该事项有助于公司实现整合资源、提升产能利用及扩大普药销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590375842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590375842?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:51","pubTimestamp":1765327871,"startTime":"0","endTime":"0","summary":"投资者提问：据报道91届药交会上，汉森制药携省级联盟集采产品四磨汤口服液、银杏叶胶囊，基药产品缩泉胶囊、感冒清热颗粒，特色产品天麻醒脑胶囊、百贝益肺胶囊、参七心疏胶囊参展，重磅推出汉森普药贴牌直招，请问贵公司推出汉森普药贴牌直招是对公司来说是利好吗，如何看待后续业务合规性，谢谢汉森制药回复：尊敬的投资者您好，该事项有助于公司实现整合资源、提升产能利用及扩大普药销售。公司将坚持合规生产与经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","BK0239","002412"],"gpt_icon":0},{"id":"2588803353","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803353?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:12","pubTimestamp":1764663144,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日的股东人数是多少？谢谢汉森制药回复：投资者您好，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200019544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0},{"id":"2586385411","title":"汉森制药：苁蓉颗粒处于工艺中试放大阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2586385411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586385411?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:33","pubTimestamp":1764030785,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司在研发方面有取得进展成果吗？谢谢汉森制药回复：尊敬的投资者您好，公司在研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。后续如有重大进展情况，将严格遵守信息披露相关规定。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0039","BK0239"],"gpt_icon":0},{"id":"2585599468","title":"汉森制药(002412)10月31日股东户数2.39万户，较上期增加2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585599468","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585599468?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:47","pubTimestamp":1763977633,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汉森制药披露，截至2025年10月31日公司股东户数为2.39万户，较9月30日增加643.0户，增幅为2.76%。在中药行业个股中，汉森制药股东户数低于行业平均水平，截至10月31日，中药行业平均股东户数为5.34万户。从股价来看，2025年9月30日至2025年10月31日，汉森制药区间涨幅为0.16%，在此期间股东户数增加643.0户，增幅为2.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0239","BK0028","002412"],"gpt_icon":0},{"id":"2584916844","title":"汉森制药：目前公司暂无海外客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2584916844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584916844?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:15","pubTimestamp":1763540127,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司通过多年经营，树立了良好的口碑和较好的用户基础，请问有无海外的客户基础？如果有，是否涉及欧盟国家？汉森制药回复：尊敬的投资者您好，目前公司暂无海外客户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900023030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0239","BK0039"],"gpt_icon":0},{"id":"2583549984","title":"汉森制药：有感冒清热颗粒等感冒药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583549984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583549984?lang=zh_cn&edition=full","pubTime":"2025-11-14 08:45","pubTimestamp":1763081113,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：今冬明春流感暴发，汉森制药有感冒药吗？谢谢汉森制药回复：尊敬的投资者您好，公司（含全资子公司）有治疗感冒的相关产品，如感冒清热颗粒、百贝益肺胶囊、复方氨酚烷胺片、藿香正气水等。具体产品信息您可查阅公司官网。药品使用谨遵医嘱！感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400006186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002412","BK0039"],"gpt_icon":0},{"id":"2583059184","title":"汉森制药（002412）披露2025年第一次临时股东大会决议公告，11月13日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059184","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583059184?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:50","pubTimestamp":1763045429,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，汉森制药报收于6.96元，较前一交易日上涨1.46%，最新总市值为35.02亿元。近日，汉森制药发布2025年第一次临时股东大会决议公告。公告显示，公司于2025年11月13日召开2025年第一次临时股东大会，会议由董事会召集，董事长刘正清主持。出席股东及授权代表共102人，代表有表决权股份221,226,929股，占公司总股本的43.9640%。湖南启元律师事务所对本次会议出具法律意见书，认为会议召集、召开程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2583599661","title":"汉森制药：选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599661","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599661?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:08","pubTimestamp":1763042880,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月13日晚间，汉森制药发布公告称，公司于2025年11月13日在公司一楼大会议室召开第四届第二次职工代表大会，经与会职工代表认真审议，同意选举胡琼女士为公司第六届董事会职工代表董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2292989.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2292989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002412","BK0239","BK0028","BK0039"],"gpt_icon":0},{"id":"2581637467","title":"股市必读：汉森制药(002412)股东户数2.39万户，较上期增加2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581637467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581637467?lang=zh_cn&edition=full","pubTime":"2025-11-05 03:44","pubTimestamp":1762285454,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，汉森制药报收于6.52元，上涨0.77%，换手率1.75%，成交量8.72万手，成交额5655.3万元。交易信息汇总资金流向11月4日主力资金净流出246.17万元，占总成交额4.35%；游资资金净流出17.37万元，占总成交额0.31%；散户资金净流入263.53万元，占总成交额4.66%。股本股东变化股东户数变动截至2025年10月31日，汉森制药股东户数为2.39万户，较9月30日增加643户，增幅2.76%；户均持股数量由上期的2.16万股下降至2.1万股，户均持股市值为13.39万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500002908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2579144213","title":"汉森制药：公司始终坚守中成药主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144213?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:51","pubTimestamp":1761828693,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药10月29日在投资者关系平台上答复投资者关心的问题。汉森制药业绩下滑，主因参股公司投资收益大减拖累净利润，核心业务扣非净利润同比降超8成；叠加销售费用占比超37%、三费合计占比44.62%，费用转化效率低；且长期依赖四磨汤口服液，单一产品抗风险能力弱。公司将致力于长远发展目标，为股东创造更大价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2579391522","title":"汉森制药（002412）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579391522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579391522?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:29","pubTimestamp":1761690568,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期汉森制药发布2025年三季报。根据财报显示，汉森制药增收不增利。截至本报告期末，公司营业总收入7.41亿元，同比上升6.75%，归母净利润8252.52万元，同比下降36.88%。按单季度数据看，第三季度营业总收入2.32亿元，同比上升8.62%，第三季度归母净利润1398.68万元，同比下降53.78%。如有转让股权相关重大事项，公司将会及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900009397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2578562474","title":"图解汉森制药三季报：第三季度单季净利润同比下降53.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578562474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578562474?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:13","pubTimestamp":1761588788,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药2025年三季报显示，公司主营收入7.41亿元，同比上升6.75%；归母净利润8252.52万元，同比下降36.88%；扣非净利润7713.8万元，同比下降37.24%；其中2025年第三季度，公司单季度主营收入2.32亿元，同比上升8.62%；单季度归母净利润1398.68万元，同比下降53.78%；单季度扣非净利润1236.85万元，同比下降55.92%；负债率11.77%，投资收益-5563.48万元，财务费用48.72万元，毛利率77.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2577583229","title":"汉森制药（002412）披露控股股东部分股份解除质押，10月23日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577583229","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577583229?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:26","pubTimestamp":1761229574,"startTime":"0","endTime":"0","summary":"本次解除质押股份数量为24,500,000股，占其所持股份比例11.56%，占公司总股本比例4.87%，质押起始日为2021年6月21日，解除日期为2025年10月22日，质权人为交通银行股份有限公司益阳分行。截至公告披露日，海南汉森持股数量为212,006,189股，持股比例42.13%，累计质押股份数量10,000,000股，占其所持股份比例4.72%，占公司总股本比例1.99%。已质押股份和未质押股份中无限售或冻结情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300037860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0028","BK0039"],"gpt_icon":0},{"id":"2574972941","title":"股市必读：汉森制药（002412）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972941","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574972941?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:10","pubTimestamp":1759954225,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，汉森制药报收于6.36元，下跌0.62%，换手率1.07%，成交量5.32万手，成交额3390.1万元。董秘最新回复投资者： 你好，请问作为儿童药的四磨汤口服液是否有望入选新版的国家基药目录，还有天麻醒脑胶囊，谢谢董秘： 尊敬的投资者您好，目前未见调整新版国家基药目录的官方信息。当日关注点来自交易信息汇总：9月30日主力资金净流出330.36万元，占总成交额9.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900001172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0028","BK0239"],"gpt_icon":0},{"id":"2570026659","title":"汉森制药：中药新药苁蓉颗粒处于中试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2570026659","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570026659?lang=zh_cn&edition=full","pubTime":"2025-09-26 08:51","pubTimestamp":1758847875,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司今年的研发计划里面，创新药占比多少？谢谢汉森制药回复：尊敬的投资者您好，公司在产品研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。具体情况请参考公司2024年度报告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600005457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2569754943","title":"汉森制药：截至2025年8月29日股东总数为23580人","url":"https://stock-news.laohu8.com/highlight/detail?id=2569754943","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569754943?lang=zh_cn&edition=full","pubTime":"2025-09-23 09:01","pubTimestamp":1758589283,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司9月20日的股东人数是多少？谢谢汉森制药回复：投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年8月29日，公司含信用账户合并股东名册的股东总数为：23580人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300006001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0028","BK0039"],"gpt_icon":0},{"id":"2567615732","title":"股市必读：汉森制药(002412)股东户数2.36万户，较上期减少3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567615732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567615732?lang=zh_cn&edition=full","pubTime":"2025-09-15 03:23","pubTimestamp":1757877792,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，汉森制药报收于6.74元，下跌1.03%，换手率2.68%，成交量13.33万手，成交额8946.05万元。来自公司公告汇总：汉森制药将于2025年9月19日参加湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会。股本股东变化股东户数变动截至2025年8月29日，公司股东户数为2.36万户，较7月31日减少838户，减幅为3.43%。户均持股数量由上期的2.06万股增加至2.13万股，户均持股市值为14.32万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","BK0028","002412"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766513959030,"stockEarnings":[{"period":"1week","weight":0.0371},{"period":"1month","weight":0.0276},{"period":"3month","weight":0.0452},{"period":"6month","weight":0.0753},{"period":"1year","weight":0.1109},{"period":"ytd","weight":0.1165}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南汉森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24145人(较上一季度增加0.85%)","perCapita":"20618股","listingDate":"2010-05-25","address":"湖南省益阳市赫山区银城大道2688号","registeredCapital":"50320万元","survey":"　　湖南汉森制药股份有限公司的主营业务是生产中药制剂、化学药。公司的主要产品是四磨汤口服液、缩泉胶囊、银杏叶胶囊、天麻醒脑胶囊、愈伤灵胶囊、百贝益肺胶囊、利胆止痛胶囊、胃肠灵胶囊、藿香正气水、玉竹膏、通关藤胶囊、参七心疏胶囊、感冒清热颗粒、人工牛黄甲硝唑胶囊、氢溴酸右美沙芬颗粒、复方氨酚烷胺片、卡托普利片、甲硝唑片、碳酸氢钠片、碘海醇注射液、碘帕醇注射液、泛影葡胺注射液。","listedPrice":35.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汉森制药,002412,汉森制药股票,汉森制药股票老虎,汉森制药股票老虎国际,汉森制药行情,汉森制药股票行情,汉森制药股价,汉森制药股市,汉森制药股票价格,汉森制药股票交易,汉森制药股票购买,汉森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}